ENDPOINTS NEWS

#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%

about 1 hour ago

Roche on Saturday detailed just how much its BTK inhibitor was deemed...

Takeda, Iambic sign multiyear R&D deal for AI drug discovery

about 2 hours ago

Takeda has signed another AI-focused deal, this time focusing on small molecules...

Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages

about 3 hours ago

Novo Nordisk on Monday said it is suing telehealth company Hims &amp...

Lilly signs another partnership with Innovent for cancer and immune diseases

about 6 hours ago

Eli Lilly is expanding its collaboration with Innovent Biologics through a new...

Hims says it will stop selling GLP-1 pill, after legal pressure from US

2 days ago

The telehealth company Hims & Hers said it will no longer sell...

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS

2 days ago

Sanofi has raised the curtain on data from an unsuccessful Phase 3...

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

2 days ago

Welcome back to another edition of Endpoints Weekly! It’s Super Bowl weekend...

US calls for DOJ investigation of Hims over GLP-1 drugs

3 days ago

TrumpRx launch falls flat for some, citing generic access

3 days ago

When President Donald Trump unveiled his anticipated direct-to-consumer drug platform on Thursday...

HHS drops legal fight over blocked 340B rebate pilot

3 days ago

The Trump administration is taking a step back from its planned 340B...

Orphan drug tweak in US spending bill will make life easier for the FDA

3 days ago

The FDA can continue to grant seven years of exclusivity for orphan...

Agomab, SpyGlass cap biggest week for biotech IPOs since 2021

3 days ago

Biotech IPOs are on the comeback Fibrosis-focused Agomab Therapeutics and eye disease...